No attachments available.
Contact Activation Pathway Function Blocking Antibody AB023
Contact and place of performance
Andy Shortall
DWG, TX 78234
USA
Request for Information Notice HT9426-26-RFI-WS03 for Contact Activation Pathway Function Blocking Antibody AB023 This is a REQUEST FOR INFORMATION (RFI) ANNOUNCEMENT ONLY. It is neither a solicitation announcement nor a request for proposals or quotes and does not obligate the Government to award a contract. Requests for a solicitation will not receive a response. Responses to this RFI must be in writing. The purpos...
View moreThe Government is not obligated to, nor will it, pay for or reimburse any costs associated with responding to this RFI. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. No subcontracting opportunity is anticipated. The North American Classification System (NAICS) code for this acquisition is 541714 – Research and Development in Biotechnology (except Nanobiotechnology); (Small Business Size Standard 1,000 employees).
Notice to potential offerors: All offerors who provide goods or services to the United States Federal Government must be registered in the System for Award Management (SAM) at www.sam.gov and complete online representations and certification in SAM.
All interested parties shall submit information by email to: [email protected], and [email protected] to be received no later than 18 June 2026, at 10:00ET.
The Defense Health Agency Contracting Activity is conducting market research under solicitation number HT9426-26-RFI-WS03 to identify qualified sources capable of providing contact activation pathway function blocking antibody AB023. This request for information supports PSC 6505 Drugs and Biologicals and NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology). The government seeks to acquire Coagulation Factor XI (FXI) Inhibitor AB023, also known as Xisomab 3G3 or Gruticibart, for use in Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-related thrombosis. Responses to this notice are due by June 18, 2026, and the primary place of performance is DWG, Texas.
The required antibody must target specific blood clotting factors to inhibit clot formation on artificial surfaces while preserving natural hemostasis and minimizing bleeding risks. The agent must bind to the "apple 2" domain of FXI to inhibit activation by factor XIIa without blocking FXI activation by thrombin or the conversion of Factor IX by activated Factor XI. The scope of work includes providing a maximum of 0.5g of AB023 annually and conducting pharmacokinetics and pharmacodynamics testing to analyze the biochemical, physiological, and molecular effects of the drug. The product must be validated through clotting assays to ensure stability and potency, causing a dose-dependent prolongation of activated partial thromboplastin time without affecting prothrombin time.
Interested parties must submit written documentation of technical expertise to Andy Shortall to demonstrate their capability to compete for the potential acquisition. Documentation must be received by 10:00 ET on the deadline date. This market research phase is intended to inform acquisition decisions and does not obligate the government to issue a solicitation or award a contract. All potential offerors must be registered in the System for Award Management, and no subcontracting opportunities are currently anticipated for this requirement.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.